Samsung Biologics Joins PSCI to Strengthen Supply Chain Ethics

• Samsung Biologics joins the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner.

• The company aims to enhance its ESG management and build resilient, decarbonized supply chains.

Samsung Biologics, a global contract development and manufacturing organisation (CDMO), announced its membership in the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner. This marks the first time a Korean CDMO has joined the PSCI, a group dedicated to excellence in safety, environmental, and social outcomes across the healthcare value chain.

The partnership will see Samsung Biologics adhere to PSCI principles covering ethics, labour, health & safety, environment, and management systems. The company expects this move to bolster its commitment to sustainable growth and enhance its Environmental, Social, and Governance (ESG) management practices.

As part of its efforts to decarbonize and build more resilient supply chains, Samsung Biologics has been actively engaging suppliers through its role in the Supply Chains Working Group within the Sustainable Market Initiative’s Health Systems Task Force. This initiative aims to promote sustainable practices and responsible business conduct across the supply chain.

“We are pleased to join the PSCI and hope to actively support collective actions to improve supply chain management,” said John Rim, CEO and President of Samsung Biologics. “As part of our commitment to deliver safe, high-quality biomedicines, we will incorporate PSCI principles into our business practices and promote responsible conduct among our suppliers to drive sustainable change across the supply chain, contributing to a healthier future.”